Company: IXHL
Filing Date: 2025-04-28
Form Type: 424B3
Source: 0001213900-25-036065
Chunk: 20

Company: Incannex Healthcare Inc.
Filing Date: 2025-04-28
Form: 424B3
Chunk 20
---
 Stock without the payment of any exercise price. A total of up to347,222,700 shares of Common Stock may be issuable upon exercise of the Series A Warrantsassuming full adjustment of the exercise price to the Floor Price and exercise pursuant to the zero exercise price provisions of the Series A Warrants .

As of April 11, 2025, the securities registered for resale by the selling stockholders in the registration statement of which this prospectus forms a part represented approximately 275.5% of the 27,546,753 shares of our Common Stock outstanding and 17.520.1% of our total shares of Common Stock outstanding assuming the exercise of all Pre-Funded Warrants and issuance of the maximum number of shares of Common Stock that may be issuable upon exercise of the Series A Warrants (assuming full adjustment of the exercise price to the Floor Price and exercise by way of the zero exercise price provisions of the Series A Warrants). Following and assuming our receipt of the Stockholder Approval to increase our authorized shares of Common Stock, we will be required to register an additional 282,894,619 shares of our Common Stock for resale upon exercise of the Series A Warrants. The securities to be registered for resale by the selling stockholders in the above referenced future resale registration statement and in the registration statement of which this prospectus forms a part would be approximately 1,260.5% of the 27,546,753 shares of our Common Stock outstanding as of April 11, 2025 and 92.19% of our total shares of Common Stock outstanding assuming the exercise of all Pre-Funded Warrants and the issuance of the maximum number of shares of Common Stock that may be issuable upon exercise of the Series A Warrants.

Our stockholders will experience substantial dilution upon the exercise of the Series A Warrants. Sales of a substantial number of shares of our Common Stock by the selling stockholders in the public market could occur at any time. Given the substantial number of shares being registered for potential resale by the selling stockholders pursuant to this prospectus and our obligations to register for resale additional shares of Common Stock for resale upon exercise of the Series A Warrants assuming receipt of the Stockholder Approval, whether as a result of substantial sales of our Common Stock by the selling stockholders or the perception in the market that holders of a large number of Shares intend to sell their Shares, the market price of shares of our Common Stock could decline significantly and the volatility of the market price of our Common